A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
  • Age: Between 18 Year(s) - 120 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Is neurologically asymptomatic from brain metastases and has not received systemic corticosteroid therapy in the 10 days prior to beginning study intervention. 2) Has not received more than 3 lines of therapy for metastatic melanoma. 3) Has adequate organ function.

You may not be eligible for this study if the following are true:

  • 1) Has a diagnosis of immunodeficiency or is receiving immunosuppressive therapy within 10 days before the first dose of study intervention. 2) Has current or history of known leptomeningeal involvement and has received stereotactic or highly conformal radiotherapy within 2 weeks before the start of dosing. 3) Has clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study drug. 4) Has untreated or unresolved intracranial hemorrhage from central nervous system (CNS) metastasis and has an active infection requiring systemic therapy.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.